Answers are grounded in this paper and cite their sources.
Treatment with engasertib decreases epistaxis frequency and duration in hereditary hemorrhagic telangiectasia, indicating a favorable safety profile.
The safety profile of engasertib was similar to that of placebo except for mild-to-moderate rash, which resolved in most patients who continued to receive the drug. Engasertib treatment was associated with decreases in epistaxis frequency and duration. (Funded by Vaderis Therapeutics; ClinicalTrials.gov number, NCT05406362.).
No takes yet. Share an insight, caveat, or question.
Al-Samkari et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: